(Total Views: 476)
Posted On: 05/06/2025 9:30:36 AM
Post# of 154603
With ESMO on everyone’s brain you might find the presentation slide deck from the December 2022 investor call of interest…there is extraordinary detail on the mTNBC study patients along with company thinking on mechanism of action. With CRC in focus those slides are also of interest. A massive amount of work went into those slides and I had forgotten how richly infused with study data they are.
https://d1io3yog0oux5.cloudfront.net/cytodyn/....22%29.pdf
Cytodyn is honing in on two exceptionally important oncologic indications:
CRC is the second deadliest and third most diagnosed cancer worldwide.
Breast cancer worldwide is the most commonly diagnosed cancer and fourth in mortality.
https://d1io3yog0oux5.cloudfront.net/cytodyn/....22%29.pdf
Cytodyn is honing in on two exceptionally important oncologic indications:
CRC is the second deadliest and third most diagnosed cancer worldwide.
Breast cancer worldwide is the most commonly diagnosed cancer and fourth in mortality.
(12)
(0)
